Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study

Abstract Background Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are a favourable option for patients with migraine who experience distressful headache disability and fail to respond to traditional preventive treatment options. However, since CGRPmAb has been available for o...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	The Journal of Headache and Pain
المؤلفون الرئيسيون:	Keiko Ihara, Seiya Ohtani, Narumi Watanabe, Nobuyuki Takahashi, Naoki Miyazaki, Kei Ishizuchi, Satoko Hori, Ryo Takemura, Jin Nakahara, Tsubasa Takizawa
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2023-03-01
الموضوعات:	Migraine Japan CGRPmAbs Headache Erenumab Galcanezumab
الوصول للمادة أونلاين:	https://doi.org/10.1186/s10194-023-01556-7

مواد مشابهة

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
حسب: Licia Grazzi, وآخرون
منشور في: (2024-02-01)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
حسب: Larry Charleston, وآخرون
منشور في: (2023-08-01)

A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland
حسب: Caroline S. Casey, وآخرون
منشور في: (2025-04-01)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
حسب: Edoardo Caronna, وآخرون
منشور في: (2021-10-01)

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
حسب: Tsubasa Takizawa, وآخرون
منشور في: (2022-12-01)

Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study
حسب: Danilo Antonio Montisano, وآخرون
منشور في: (2024-04-01)

Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
حسب: Armin Scheffler, وآخرون
منشور في: (2024-07-01)

Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment
حسب: Marcin Straburzyński, وآخرون
منشور في: (2025-04-01)

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
حسب: Antun R. Pavelic, وآخرون
منشور في: (2022-12-01)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
حسب: Hugo Sevivas, وآخرون
منشور في: (2022-06-01)

A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?
حسب: Sena Uzun, وآخرون
منشور في: (2023-05-01)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
حسب: Theodoros Mavridis, وآخرون
منشور في: (2021-07-01)

Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
حسب: Suruchi Aditya, وآخرون
منشور في: (2023-01-01)

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
حسب: Varnado OJ, وآخرون
منشور في: (2024-01-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
حسب: Davor Jančuljak, وآخرون
منشور في: (2024-01-01)

Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence
حسب: Abubker Omaer, وآخرون
منشور في: (2024-04-01)

Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
حسب: Taoufik Alsaadi, وآخرون
منشور في: (2024-02-01)

Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
حسب: Abouch V. Krymchantowski, وآخرون
منشور في: (2023-03-01)

Vertebral artery dissection in a patient with migraine treated with calcitonin gene-related peptide monoclonal antibody: a case report and FAERS database analysis
حسب: Daiki Tokuyasu, وآخرون
منشور في: (2025-01-01)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
حسب: Seiya Ohtani, وآخرون
منشور في: (2023-11-01)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
حسب: Anna V. Berdnikova, وآخرون
منشور في: (2023-10-01)

A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
حسب: V. Karpavičiūtė, وآخرون
منشور في: (2023-10-01)

A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
حسب: V. Karpavičiūtė, وآخرون
منشور في: (2023-10-01)

Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort study
حسب: Edina Szabo, وآخرون
منشور في: (2023-01-01)

Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
حسب: Elizabeth Seng, وآخرون
منشور في: (2024-09-01)

MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment
حسب: Raffaele Ornello, وآخرون
منشور في: (2024-05-01)

Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study
حسب: Bui Bao Khanh Dinh, وآخرون
منشور في: (2021-12-01)

Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data
حسب: N. V. Vashchenko, وآخرون
منشور في: (2022-01-01)

Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis
حسب: Mohamed E. Haseeb, وآخرون
منشور في: (2025-03-01)

CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society
حسب: Tsubasa Takizawa, وآخرون
منشور في: (2024-03-01)

Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome
حسب: Christina Deligianni, وآخرون
منشور في: (2023-06-01)

Assessment and characteristics of Erenumab therapy on migraine management
حسب: Haitham Saeed, وآخرون
منشور في: (2022-08-01)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
حسب: Mark E. Bangs, وآخرون
منشور في: (2020-01-01)

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
حسب: Angelo Camporeale, وآخرون
منشور في: (2018-11-01)

Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study
حسب: Takao Takeshima, وآخرون
منشور في: (2024-04-01)

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
حسب: Stephen D. Silberstein, وآخرون
منشور في: (2019-06-01)

Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat
حسب: Nadine Friedrich, وآخرون
منشور في: (2024-01-01)

Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?
حسب: Michele Torrisi, وآخرون
منشور في: (2023-05-01)

Migren Profilaksisinde Etkili Bir Ajan; Galcanezumab: Tek Merkez Deneyimleri
حسب: Sena Boncuk Ulaş, وآخرون
منشور في: (2024-09-01)

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
حسب: Giuseppe Tringali, وآخرون
منشور في: (2020-10-01)